

ROTHWELL, FIGG, ERNST & MANBECK

Suite 800
1425 K Street, N.W.
Washington, D.C. 20005

Telephone: (202)783-6040
Telex: 64285 BNPAT
Telefax: (202)783-6031

FACSIMILE TRANSMITTAL SHEET

DATE: September 2, 2005

TO: Ms. Dianne Maggarod
U.S. Patent and Trademark Office
Fax: 571-273-0300
Tel.: 571-272-4634

FROM: Kimberly Bailey for George R. Repper

OUR REF: 1194-180

SERIAL NO.: 09/971,774

MESSAGE: Further to our conversation and your instructions of September 1, 2005, attached is the revised Appendix (Claims Appendix) and newly added Appendixes (Evidence Appendix and Related Procedure Appendix) you requested.

Number of Pages Including This Transmittal Sheet: 6

If any problems in connection with this facsimile please contact: *Kim Bailey* at 202-626-3502.

THIS MESSAGE IS INTENDED FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR THE EMPLOYEE OR AGENCY RESPONSIBLE FOR DELIVERING THE MESSAGE TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US AT THE ABOVE ADDRESS VIA THE U.S. POSTAL SERVICES. THANK YOU.

Serial No. 09/971,774

Page 13

CLAIMS APPENDIX

1. A method of treating abdominal cancer comprising performing a surgery on a patient's abdomen by forming a surgical opening in said patient's abdomen, surgically removing a cancerous tumor from the patient's abdomen through the surgical opening, and closing said surgical opening, the method including a step of administering taurolidine, taurultam or a mixture thereof to the patient's abdomen prior to said closing of said surgical opening and after said surgically removing said cancerous tumor, so as to treat cancer in the patient's abdomen, further including a step of additionally administering taurolidine, taurultam or a mixture thereof to said patient after said closing said surgical opening.

2. The method of claim 1 wherein, after closing said surgical opening, said taurolidine, taurultam or mixture thereof is administered to said patient by installation or intravenous infusion.

3. The method of claim 2 wherein, further including the step of additionally administering taurolidine, taurultam or a mixture thereof to said patient prior to forming said surgical opening in said patient's abdomen.

4. The method of claim 1, further including the step of additionally administering taurolidine, taurultam or a mixture thereof to said patient prior to forming said surgical opening in said patient's abdomen.

Serial No. 09/971,774
Page 14

5. The method of claim 1, wherein performing said surgery on said patient includes introducing a trocar tube into said patient during laparoscopic tumor surgery so as to conduct laparoscopic tumor surgery so as to conduct laparoscopic tumor surgery utilizing said trocar tube.

6. The method of claim 5 wherein during said surgery, said administering said taurolidine, taurultam or mixture thereof to said patient's abdomen is conducted by passing a solution containing said taurolidine, taurultam or mixture thereof through said trocar tube so as to contact internal tissue of the patient with said solution.

7. The method of claim 6 further comprising the step of withdrawing said trocar from said patient prior to said closing said surgical opening and prior to said step of additionally administering said taurolidine, taurultam or mixture thereof to said patient after closing said surgical opening.

8. The method of claim 1 wherein said taurolidine, taurultam or a mixture thereof is present in a solution containing from 0.5 to 3% by weight said taurolidine or from 2 to 3% by weight said taurultam, or a mixture thereof.

9. The method of claim 8 wherein said solution further contains heparin, a heparin derivative or hyaluronic acid.

10. The method of claim 6 further comprising the step of additionally introducing said solution into said patient prior to said laparoscopic tumor surgery and prior to introducing said trocar tube into said patient.

11. The method of claim 5 wherein said cancerous tumor is selected from the group consisting of oesophagus carcinoma, cardiac carcinoma, malignant degenerative ulcer, stomach carcinoma, antrum carcinoma, corpus carcinoma, align adenoma of island cells, gall duct carcinoma, distal choledochus carcinoma, pancreas head carcinoma, pancreas papilla carcinoma, pancreas corpus carcinoma, pancreas cauda carcinoma, small intestinal tract carcinoma, large intestinal tract carcinoma, sarcoma, colon malignancy, adeno carcinoma, lymphoma, malign carcinoid, melanoma, rectal carcinoma, ovarian carcinoma, mamma carcinoma, and prostate carcinoma.

12. The method of claim 1 wherein said cancerous tumor is selected from the group consisting of colon cancer, rectal cancer, pancreatic cancer, stomach cancer and lung cancer.

26. The method of claim 1 further comprising administering to said patient 5-fluorouracil (5-FU) at a dosage within a range of about 0.1-1,000 mg.

Serial No. 09/971,774
Page 16

EVIDENCE APPENDIX

None.

Serial No. 09/971,774
Page 17

RELATED PROCEDURE APPENDIX

None.